Non-Small Cell Carcinoma — Research

Non-Small Cell Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	1,188	`("Non-Small Cell Carcinoma"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	218	`("Non-Small Cell Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	34	`("Non-Small Cell Carcinoma"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (372)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 201–225 of 372 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
· Cancer · 2016 · PMID 27315356 · validated civic_curation pubmed
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
· PLoS One · 2016 · PMID 27032107 · validated civic_curation pubmed
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
· BMC Cancer · 2019 · PMID 31208370 · validated civic_curation pubmed
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.